|
rs8187710
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Only one polymorphism was validated across both cohorts for an association with overall survival: the A allele of the ABCC2 polymorphism, rs8187710 (4544G>A), was associated with adverse overall survival (adjusted hazard ratio [aHR] 2.22; 95% CI: 1.2-4.0; p=0.009) among our stage IV NSCLC patients.
|
26816351 |
2016 |
|
rs121913236
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Herein we identified a KRAS Q22K mutation and frameshift mutations in the genes encoding serine/threonine kinase 11 (STK11) and ataxia telangiectasia mutated serine/threonine kinase (ATM) by next-generation sequencing in a patient with ALK rearrangement-positive oligo-metastatic NSCLC, whose disease progressed while on two ALK-targeted therapies.
|
25964588 |
2015 |
|
rs1051730
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.
|
19733931 |
2010 |
|
rs1217691063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we have examined the SNP of methylenetetrahydrofolate reductase (MTHFR) C677T, which affects DNA methylation patterns and is linked to elevated plasma homocysteine levels in 208 patients with gemcitabine/cisplatin-treated stage IV non-small-cell lung cancer (NSCLC).
|
15217535 |
2004 |
|
rs372043866
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
|
30506139 |
2018 |
|
rs372043866
|
|
|
0.020 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation.
|
29595366 |
2019 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation.
|
29595366 |
2019 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
|
30121602 |
2018 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Outcomes in patients with stage iv nsclc harbouring <i>BRAF</i> V600E mutations (<i>n</i> = 32) did not differ significantly from those of patients with other <i>BRAF</i> mutations.
|
30464690 |
2018 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
|
30121602 |
2018 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Outcomes in patients with stage iv nsclc harbouring <i>BRAF</i> V600E mutations (<i>n</i> = 32) did not differ significantly from those of patients with other <i>BRAF</i> mutations.
|
30464690 |
2018 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
|
27283860 |
2016 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
|
27283860 |
2016 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
|
29242281 |
2018 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M.
|
28961841 |
2017 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The European Commision (EC) recently approved osimertinib for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR T790M mutations.
|
28884371 |
2017 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
|
28367058 |
2017 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
|
27784815 |
2016 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
There is limited information available concerning the prevalence of primary T790M mutations in patients with metastatic NSCLC tumors before treatment with EGFR-TKIs.
|
24789720 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy.
|
31486987 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To assess the utility of the <b>cobas</b> EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with <i>EGFR</i>-mutated (<i>EGFR</i>m; Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125).
|
31439584 |
2019 |